Press Releases

GI Dynamics, Inc. Announces Completion of A $1.5million Private Placement and Launch of Security Purchase Plan

GI Dynamics®, (ASX:GID) a medical technology company that has developed an innovative device to improve outcomes for patients diagnosed with type 2 diabetes and obesity is pleased to announce that it has received commitments for a private placement of 69,865,000 fully paid CHESS Depositary...

read more

EndoBarrier® Makes Advancement Toward German Reimbursement

EndoBarrier® Makes Advancement Toward German Reimbursement GI Dynamics®, Inc. (ASX: GID), a medical technology company that has developed an innovative device to improve outcomes for patients with type 2 diabetes and obesity, continues to make progress toward full reimbursement in Germany. Germany...

read more

German Registry Releases Positive EndoBarrier Data at EASD

German Registry Releases Positive EndoBarrier Data at EASD BOSTON, Massachusetts, United States, and SYDNEY, Australia – November 9, 2016, AEDT Mean reduction in absolute HbA1c of 1.3% Insulin usage dropped 42% GLP-1 usage reduced in 78% of patients Excess weight loss of 15kg, or 29% of excess...

read more

TGA Cancellation of EndoBarrier Listing

TGA Cancellation of EndoBarrier Listing GI Dynamics, Inc. (ASX: GID) (GI Dynamics or the Company), a medical technology company that has developed an innovative device to improve outcomes for patients diagnosed with type 2 diabetes and obesity, has received final cancellation notification from the...

read more

Appendix 4C: Quarter ended 30 June 2016

Appendix 4C: Quarter ended 30 June 2016 GI Dynamics, Inc. (ASX: GID) (the Company), a medical technology company that has developed an innovative device to improve outcomes for patients battling type 2 diabetes and obesity, today released its Appendix 4C — Quarterly Cash Flow Report for the...

read more

Final Efficacy and Safety Results of U.S. ENDO Trial Announced at ADA

Final Efficacy and Safety Results of U.S. ENDO Trial Announced at ADA Statistically and clinically significant efficacy: 1.1% absolute reduction in HbA1c Statistically and clinically significant efficacy: 7.7% reduction in body weight 34.8% of patients achieved the ADA target of HbA1c ≤ 7.0% after...

read more

Results of EndoBarrier Therapy Studies Presented at Digestive Disease Week Meeting

Results of EndoBarrier Therapy Studies Presented at Digestive Disease Week Meeting EndoBarrier mechanism-of-action study shows ~18 kg mean weight loss and negative correlation between fat absorption and weight loss1 EndoBarrier treatment shows reduction in hepatic fat of 81% and 6x liraglutide...

read more

EndoBarrier Therapy Data to be Presented at American Diabetes Association Annual Meeting

EndoBarrier Therapy Data to be Presented at American Diabetes Association Annual Meeting LEXINGTON, Massachusetts and SYDNEY, Australia – 9 June 2016 – GI Dynamics, Inc. (ASX:GID), a medical device company that has developed an innovative endoscopically delivered treatment for type 2 diabetes and...

read more

GI Dynamics Appoints Chief Compliance Officer

GI Dynamics Appoints Chief Compliance Officer LEXINGTON, Mass & SYDNEY, Australia – 10 May 2016 AEST – GI Dynamics, Inc. (ASX: GID) (the Company), a medical device company that provides an innovative treatment for type 2 diabetes and obesity, today announces the appointment of Brian Callahan...

read more

GI Dynamics Releases Safety and Efficacy Data for EndoBarrier Therapy

GI Dynamics Releases Safety and Efficacy Data for EndoBarrier Therapy LEXINGTON, Massachusetts and SYDNEY, Australia – 9 May 2016 AEST – GI Dynamics, Inc. (ASX:GID), a medical device company that develops innovative endoscopically delivered treatments for type 2 diabetes and obesity, announced new...

read more
Page 1 of 212